Avantax Planning Partners, Inc. Contrafect Corp Transaction History

Avantax Planning Partners, Inc.

  • $3.1 Billion
  • Q2 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Oct 14, 2022
BUY
$0.18 - $3.51 $12,600 - $245,699
70,000 Added 466.67%
85,000 $14,000
Q1 2021

May 06, 2021
BUY
$4.46 - $6.68 $66,900 - $100,200
15,000 New
15,000 $72,000

Others Institutions Holding CFRX

# of Institutions
2
Shares Held
49.2K
Call Options Held
0
Put Options Held
0
View Full List

About CONTRAFECT Corp

CFRX Quotes by TradingView
  • Ticker CFRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,332,700
  • Market Cap $1.18M
  • Description
  • ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...
More about CFRX
Track This Portfolio

Track Avantax Planning Partners, Inc. Portfolio

Follow Avantax Planning Partners, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Avantax Planning Partners, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Avantax Planning Partners, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email